A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Chris Galloway, MD
Davia Clinical Research
Principal Investigator - Thomas Marbury, MD
Orlando Clinical Research Center
Principal Investigator - William Smith, MD
New Orleans Center for Clinical Research
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Davita Clinical Research
Lakewood, Colorado, United States
- Orlando Clinical Research Center
Orlando, Florida, United States
- New Orleans Center for Clinical Research
Knoxville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2013
- Primary completion
- 28 Feb 2014
- Completion
- 31 Mar 2014
- Last update posted
- 17 Dec 2021
- Registered enrollment
- 24
- Registry id
- NCT02135302
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.